Results 161 to 170 of about 291,430 (249)

Complete issue

CAML Review / Revue de l'ACBM, 2010
openaire   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Artificial Intelligence for Medicines Information: Scoping Review of Clinical Applications and Digital Health Inequalities.

J Med Internet Res
Al-Arkee S, Falade J, Paudyal V.
europepmc   +1 more source

Evaluating the usefulness of ChatGPT and Gemini in generating educational content for patients with vitiligo: a comparative cross-sectional study. [PDF]

Proc (Bayl Univ Med Cent)
Tamer F, Polat M.
europepmc   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Predictive hybrid scan-to-BIM method improves heritage building documentation completeness and accuracy. [PDF]

Sci Rep
Salah R, Géczy N, Ajtayné Károlyfi K.
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Improving the Completeness of Surgical Consent Documentation Through a Closed-Loop Quality Improvement Audit at a Secondary Care Teaching Hospital. [PDF]

Cureus
Homaida H, Ahmed ZKA, Abdelal A, Awad SA, Mohammed G, Adam Suliman HO, Edris EMA, Adam ASM, Mohamed M, Ali Fadul MA, Ali RH, Ahmed A, Abdalla MA, Elnour MAAE, Ibrahim IH, Yousif TM, Muhammed A, Mohamed MAA.   +17 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Bridging data gaps in pregnancy outcomes: a four-year review of gestational Age records and delivery trends in Kilimanjaro region, Tanzania. [PDF]

Front Reprod Health
Msoka A, Lyimo A, Nkya G, Zongollo P, Lyimo G, Khanga JN, Rashid F, Mitao M, Oshosen M, Mmbaga BT.   +9 more
europepmc   +1 more source